|
⚲
|
| Keyboard |
| Matrix Capital Management Company LP
✚
|
|
|---|---|
| CRD # | 160066 |
| SEC # | 801-73612 |
| CIK # | 0001410830, 0001906866 |
| AUM | 2,323.7 M (2026-03-31) |
| Employees | 7 (57% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 603-956-9151 |
| Address | 3 Pleasant Street Portsmouth, NH 03801 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation The fees applicable to each Fund are set forth in detail in each Fund’s governing documents (“Governing Documents”). Generally, the Firm is paid a fee for its advisory services (the “Management Fee”). Additionally, the General Partners may receive incentive allocations or carried interest (as applicable) (“Performance Allocation”). The Firm may, and has, in its discretion, agreed to waive all or a portion of the Management Fee with respect to a capital account or, with the consent of the investors, charge a Management Fee on a different basis or at a different rate. The Firm has the discretion to waive the payment of any Management Fee or Performance Allocation. The Firm reduces or waives Management Fees and/or Performance Allocation for certain affiliates and related persons of the Firm, including, without limitation, limited partners that are employees or partners of the Firm and/or their immediate family members, and accounts established for the benefit of such persons. As more fully described in each Fund’s respective Governing Documents, the Funds will generally bear expenses in connection with their organizational matters and investment activities, in certain cases subject to an expense cap. The Firm will allocate expenses in accordance with its expense allocation policies and procedures. Certain expenses are the obligation of a particular Fund and are borne by such Fund. Conversely, certain expenses relate to more than one Fund and in such instances are generally allocated among such Funds on a pro rata basis. Neither Matrix, AyurMaya or any of its supervised persons accept any other forms of compensation. A. Matrix Capital Management Company, LP Management Fee Matrix is paid a Management Fee, payable quarterly in advance, with respect to each capital account. Effective as of January 1, 2025, the Management Fee from the Matrix Funds is equal to 0.25% (1% annualized) of such capital account’s balance. The Management Fee is calculated and payable as of the first day of each calendar quarter, giving effect to any contributions on that day. A pro rata Management Fee is assessed on any capital contributions accepted as of any date other than the first day of the quarter and charged to the capital account of the contributing investor. If an investor withdraws all or a portion of the balance of a capital account other than on the last business day of a calendar quarter, Matrix will repay to the Matrix Fund for disbursement to the withdrawing investor a pro rata portion of the Management Fee charged to such capital account. Without consent of the investors, the Management Fee may be charged to, and paid by, the Master Fund, instead of the Feeder Funds. Performance Allocation Matrix receives a Performance Allocation generally equal to 20% of realized and unrealized net profits of each Feeder Fund for each fiscal year; provided, that each such Fund maintains a bookkeeping account to determine the high-water mark (a “Loss Recovery Account”) that must be exceeded before the performance-based compensation with respect to an investor in a Matrix Fund is charged at a rate of 20%. The Loss Recovery Account of each investor in a Matrix Fund commences at zero. As of each adjustment date, the Loss Recovery Accounts of each Matrix Fund is either (i) increased by an amount equal to two and one-half times (250%) of any net loss allocated for such fiscal period or (ii) decreased (but not below zero) by the amount of any net profit allocated for such fiscal period. An investor will bear a Reduced Performance Allocation equal to 10% of its realized and unrealized net profits until the balance of its Loss Recovery Account is reduced to zero, and a Performance Allocation at the 20% rate thereafter. Unless otherwise determined by Matrix, in the event that a Matrix Fund is terminated or an investor withdraws or redeems other than at the end of a fiscal year, then for purposes of determining the applicable Performance Allocation, net capital appreciation will be determined as if such dates were the end of the fiscal year, subject to certain adjustments. Effective October 1, 2025, Matrix adopted changing the performance fee from a traditional "hedge fund" arrangement calculated on the basis of realized and unrealized gains and looses to a traditional "private equity style" waterfall. The new performance compensation structure will be a back-ended, European-style waterfall model. Under this structure, Matrix will not receive its performance compensation (in the form of “carried interest”) until all investors have received (x) a full return of their capital account balances as of October 1, 2025, and (y) a full recovery of the Loss Recovery Account calculated as of September 30, 2025, consistent with the methodology used under the existing hedge fund fee arrangement. Any carried interest distributions will be subject to an after-tax clawback if, upon the final liquidation of the Fund, Matrix actually receives carried interest distributions in excess of the carried interest distributions it is entitled to receive under the distribution waterfall (net of taxes to which Matrix and its members bear in respect of such carried interest distributions). In addition, to accommodate the Matrix’s (and its partners’) periodic tax obligations with respect to allocations of income in respect of carried interest, the Fund will allow the Matrix to receive distributions to cover taxes on such allocated taxable income. Importantly, the Fund will no longer apply the modified high-water mark provision in connection with calculating performance compensation. The carried interest “rate” will be fixed at 10% across all investors. Under the new performance compensation structure, there will be no preferred return or catch-up provision. Expenses Matrix bears its own overhead expenses incurred in connection with managing the Matrix Funds, ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7 – Types of Clients Matrix and AyurMaya provide investment advisory services to the Matrix Funds and AyurMaya Fund, respectively. The Funds are formed as partnerships and limited companies in the U.S. and Cayman Islands. Interests in the Funds were offered pursuant to applicable exemptions from registration under the Securities Act of 1933 (“Securities Act”) and the 1940 Act. Investors in the Funds are generally “qualified purchasers” or “knowledgeable employees,” each as defined in the 1940 Act (and rules promulgated thereunder) and may include, among others, U.S. and foreign- based high net worth individuals, corporations, trusts, institutions, financial institutions, and government entities. The Matrix Funds and AyurMaya Fund impose a minimum initial investment of $5 million, which may be waived at the discretion of Matrix and AyurMaya respectively. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| AURA Biosciences Inc | 0.0 | ||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Ayurmaya Capital Management Fund LP | [2021-12-15] | 655.0 M | 756.9 M |
| Filed 2021-12-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose | ||||
| HF | Matrix Capital Management Fund II LP | [2012-02-14] | 25.4 M | 46.9 M |
| Filed 2017-03-21 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $50,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Matrix Capital Management Master Fund LP | [2012-02-14] | 1,327.5 M | 1,566.8 M |
| Filed 2025-03-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $48,138 · Net Assets Decline to Disclose | ||||
| HF | Matrix Capital Management Restricted Investment Fund LP | 2012-02-14 | 10.4 M | |
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 4 | 2.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 4 | 2.3 |
| By Discretionary | ||
| Discretionary | 4 | 2.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 4 | 2.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.6 | |
| United States Persons | 1.7 | |
| Total | 4 | 2.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Laren Gillespie | Director | 119 | 24 | |
| Lisa Alexander | Director | 75 | 17 | |
| Richard Ruffer | Director | 425 | 15 | |
| Christine Fletcher | Director | 72 | 13 | |
| Alison Martinson | Director | 38 | 13 | |
| Gregory Brown | Director | 31 | 3 | |
| David Goel | Director, Executive Officer | 13 | 2 | |
| Matrix General Partner LP | Executive Officer | 2 | 2 | |
| Matrix General Partner LLC | Executive Officer | 2 | 2 | |
| Ayurmaya General Partner LLC | Executive Officer | 1 | 1 | |
| Timothy Frechette | Director | 1 | 1 | |
| Ayur Maya Capital Management Company LP | Promoter | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001410830] | |
| 3 | [0001410830] | |
| 4 | [0001410830] | |
| SC 13D | [0001410830] | |
| SC 13G | [0001410830] | |
| 13F-HR | [0001906866] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $1.5B |
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 549300CAYJ90YENRRB21 |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Matrix Capital Management Company LP | |
| Aura Biosciences Inc | |
| GOEL David E | |
| Zentalis Pharmaceuticals Inc | |
| Adaptive Biotechnologies Corp |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
|
2025-12-15 | Sell | 7,500,000 | $1.33 | 9,975,000 |
|
Aura Biosciences Inc AURA
Common Stock, par value $0.00001 per share (Common Stock)
|
2023-11-09 | Buy | 1,560,000 | $9.00 | 14,040,000 |
|
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
|
2023-06-20 | Buy | 4,760,000 | $22.66 | 107,861,600 |
|
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
|
2022-12-05 | Buy | 1,250,000 | $12.00 | 15,000,000 |
|
Aura Biosciences Inc AURA
Common Stock
|
2021-11-02 | Buy | 1,785,000 | $14.00 | 24,990,000 |
|
Aura Biosciences Inc AURA
Series E Convertible Preferred Stock · derivative
|
2021-11-02 | Conversion | 2,327,870 | $0.00 | |
|
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
|
2021-11-02 | Conversion | 2,327,870 | ||
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-10 | Sell | 30,268 | $42.38 | 1,282,758 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-10 | Sell | 25,732 | $41.47 | 1,067,106 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-09 | Sell | 34,302 | $41.16 | 1,411,870 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-09 | Sell | 215,698 | $40.42 | 8,718,513 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 71,194 | $41.21 | 2,933,905 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 234,295 | $38.22 | 8,954,755 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 75,000 | $39.22 | 2,941,500 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 33,600 | $39.97 | 1,342,992 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 85,911 | $41.62 | 3,575,616 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2020-07-20 | Sell | 2,000,000 | $40.00 | 80,000,000 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2020-01-24 | Conversion | 2,217,101 | $26.50 | 58,753,176 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2019-07-01 | Conversion | 84,359 | ||
|
Adaptive Biotechnologies Corp ADPT
Series E-1 Convertible Preferred Stock · derivative
|
2019-07-01 | Conversion | 5,893,716 | $0.00 | |
| showing 20 of 26 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Oxford Finance Advisors LLC
✚
|
VA | 2,406.9 M |
|
Irenic Capital Management LP
✚
|
NY | 2,398.7 M |
|
Broadriver Asset Management LP
✚
|
NY | 2,342.3 M |
|
Tiptree Advisors LLC
✚
|
NY | 2,310.8 M |
|
SageView Capital LP
✚
|
CT | 2,307.2 M |
|
Varadero Capital LP
✚
|
NY | 2,292.2 M |
|
Waratah Capital Advisors Ltd
✚
|
2,271.0 M | |
|
Coliseum Capital Management LLC
✚
|
CT | 2,269.4 M |
|
Teng Yue Partners LP
✚
|
NY | 2,247.5 M |
|
Mason Capital Management LLC
✚
|
NY | 2,237.5 M |